Page 10 - Update on the treatment options in Kidney Cancer

CheckMate 214

Overall Survival: by IMDC Risk

Intermediate/poor risk Favorable risk

Median OS, months (95% CI) Median OS, months (95% CI)

NIVO+IPI NR (35.6–NE) NIVO+IPI NR (NE)
SUN 26.6 (22.1–33.4) SUN NR (NE)

HR (95% CI), 0.66 (0.54–0.80) HR (95% CI), 1.22 (0.73–2.04)
P < 0.0001 96% P = 0.4426
1.0 1.0
0.9 80% 66% 0.9 94% 88% 85% SUN
Overall survival (probability) 0.7 72% 53% 60% NIVO+IPI Overall survival (probability) 0.7 NIVO+IPI

0.8
0.8

85%

80%
0.6
0.6

0.5
0.5

0.4
0.4
47%
SUN
0.3
0.2
0.2
0.1 0.3
0.1
0.0 0.0
0 3 6 9 12 15 18 21 24 27 30 33 36 3 9 4 2 4 5 0 3 6 9 12 15 18 21 24 27 30 33 36 3 9 4 2 4 5
Months Months
No. at risk No. at risk
NIVO+IPI 425 399 372 348 332 317 306 287 270 253 233 183 90 34 2 0 NIVO+IPI 125 124 120 116 111 108 104 102 101 98 94 88 71 24 2 0
SUN 422 388 353 318 290 257 236 220 207 194 179 144 75 29 3 0 SUN 124 119 119 117 114 110 109 105 103 101 96 88 70 26 2 0